Dapsone in the treatment of pemphigus vulgaris: adverse effects and its importance as a corticosteroid sparing agent
AUTOR(ES)
Quaresma, Maria Victória, Bernardes Filho, Fred, Hezel, Janaína, Peretti, Murilo Calvo, Kac, Bernard Kawa, Azulay-Abulafia, Luna
FONTE
An. Bras. Dermatol.
DATA DE PUBLICAÇÃO
2015-06
RESUMO
AbstractPemphigus vulgaris is an autoimmune disease characterized by suprabasal blisters with acantholysis, which has a fatal course in a large number of untreated patients. Systemic corticosteroid therapy is considered first-line therapy. Adjuvant treatment with the goal of sparing corticosteroids include, among others, dapsone. This drug is not without side effects and its use requires clinical and laboratory control. We present a patient with PV initially managed with suboptimal dose of prednisone, evolving into drug-induced hepatitis after introduction of dapsone.
Documentos Relacionados
- Pemphigus vulgaris: the other half of the story
- Nialamide as a “Steroid Sparing” Agent in the Treatment of Rheumatoid Arthritis
- Correlation of peptide specificity and IgG subclass with pathogenic and nonpathogenic autoantibodies in pemphigus vulgaris: a model for autoimmunity.
- Adverse effects of topical corticosteroid use.
- Can methotrexate be used as a steroid sparing agent in the treatment of polymyalgia rheumatica and giant cell arteritis?
